C-Reactive Protein is a Prognostic Marker for Patients with Castration-Resistant Prostate Cancer

2016 ◽  
Vol 39 (5) ◽  
pp. 266-271 ◽  
Author(s):  
Shao-Guang Liao ◽  
Hui-Hua Cheng ◽  
Yong Lei
Keyword(s):  
Prostate Cancer ◽  
Prognostic Marker ◽  
Castration Resistant Prostate Cancer ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Castration Resistant

Chemotherapy in hormone-refractory prostate cancer: Docetaxel with and without VT122.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e16062-e16062
Author(s):  
Gouri Shankar Bhattacharyya ◽  
Newell Bascomb ◽  
Hemant Malhotra ◽  
Ghanashyam Biswas ◽  
Shailesh Arjun Bondarde
Keyword(s):  
Prostate Cancer ◽  
Randomized Study ◽  
Castration Resistant Prostate Cancer ◽  
Protein Levels ◽  
Reactive Protein ◽  
End Point ◽  
Castration Resistant ◽  
Number Of Patients ◽  
Duration Of Response ◽  
Hormone Refractory

e16062 Background: Randomized study in metastatic castration resistant prostate cancer treated with docetaxel and the benefit of adding VT122. Methods: Castration resistant prostate cancer with bone metastasis, symptomatic were treated with docetaxel 75 mg/m2 every 3 week and prednisolone with continued androgen suppression, LHRH analogue and zoledronic acid, every 28 days with or without VT122. VT122 is a drug combination of etodolac, a COX-2 inhibitor and propranolol, a beta blocker with anti angiogenic properties; this combination has previously been shown to be anti cachectic, anti neoplastic.The dose of etodolac was titrated by C-reactive protein levels to a maximum of 800 mg/day. The dose of propranolol was titrated to keep heart rate at around 60 b/min to 70 b/min. GCSF was allowed, all patients were given Calcium and VitaminD. The primary end point was time to progression, a composite end point of objective progression by RECIST criteria, PSA progression or pain progression, whichever occurred first was applied.The McGill questionnaire was applied to patients. Number of patients 69; 34 in docetaxel arm; 35 in VT122 arm. Age between 50-65 years. Taken from 3 centers with PS ECOG <2 controlled comorbidity with stable analgesic regime. All patients were planned for 6 cycles of docetaxel. Follow-up was for a period of two years. Results: Median age of 62 years with ECOG status 1 was seen in 88%. The median PSA value was seen as 138 ng/ml (10 - 600). 66% in both arms had measurable disease. Conclusions: Addition of VT122 improves response rates, duration of response and symptom scales along with 1-year survival which are statistically significant; toxicities are also significantly decreased and indicating increased efficacy and safety profile of docetaxel. The efficacy and control of toxicity and easy to administer makes this an attractive combination. [Table: see text]

Germline genetic variation inJAK2as a prognostic marker in castration-resistant prostate cancer

2016 ◽  
Vol 119 (3) ◽  
pp. 489-495 ◽  
Author(s):  
Ben Y. Zhang ◽  
Shaun M. Riska ◽  
Douglas W. Mahoney ◽  
Brian A. Costello ◽  
Rhea Kohli ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Genetic Variation ◽  
Prognostic Marker ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant
Sign in / Sign up

Export Citation Format

Share Document